Keryx Biopharmaceuticals (KERX) reported quarterly earnings results on Thursday, Apr-28-2016. The company reported $-0.39 earnings per share for the quarter, missing the analyst consensus estimate by $-0.15. Analysts had a consensus of $-0.24. The company posted revenue of $6.80 million in the period, compared to analysts expectations of $6.96 million. The company’s revenue was up 466.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.28 EPS.
Many Wall Street Analysts have commented on Keryx Biopharmaceuticals. Company shares were Reiterated by FBR Capital on Mar 30, 2016 to “Outperform”, Firm has raised the Price Target to $ 13 from a previous price target of $10 .FBR Capital Upgraded Keryx Biopharmaceuticals on Feb 29, 2016 to ” Outperform”, Price Target of the shares are set at $10.Shares were Reiterated by Stifel on Feb 26, 2016 to “Buy” and Lowered the Price Target to $ 9 from a previous price target of $10 .
Keryx Biopharmaceuticals opened for trading at $5.01 and hit $5.19 on the upside on Wednesday, eventually ending the session at $5.08, with a gain of 0.40% or 0.02 points. The heightened volatility saw the trading volume jump to 14,45,057 shares. Company has a market cap of $538 M.
In a different news, on Apr 27, 2016, John F. Neylan (Chief Medical Officer) sold 4,766 shares at $5.21 per share price. According to the SEC, on Apr 18, 2016, Brian Adams (VP and General Counsel) sold 1,060 shares at $5.05 per share price. On Apr 7, 2016, Greg Madison (President and CEO) sold 1,078 shares at $4.50 per share price, according to the Form-4 filing with the securities and exchange commission.
Keryx Biopharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate) an oral absorbable iron-based compound received marketing approval from the United States Food and Drug Administration (FDA) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels Auryxia’s pharmacodynamic properties resulted in increased ferritin iron and transferrin saturation (TSAT).